Valneva confirms participation in UK government COVID-19 vaccine response program
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.
MVM invests in MDxHealth SA
MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.
MVM leads investment round in SkyCell
MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.
Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15
Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.
MVM Partners LLP Closes Fund V
MVM Partners announces the closing of a $325 million healthcare fund, MVM V.
HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events
HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.